F Mignolet
About
F Mignolet is a scholar working on Cancer Research, Oncology and Genetics.
According to data from OpenAlex, F Mignolet has authored 21 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Cancer Research, 11 papers in Oncology and 4 papers in Genetics. Recurrent topics in F Mignolet's work include Breast Cancer Treatment Studies (12 papers), Cancer Treatment and Pharmacology (8 papers) and Estrogen and related hormone effects (3 papers). F Mignolet is often cited by papers focused on Breast Cancer Treatment Studies (12 papers), Cancer Treatment and Pharmacology (8 papers) and Estrogen and related hormone effects (3 papers). F Mignolet collaborates with scholars based in Belgium, Netherlands and France. F Mignolet's co-authors include Harry Bartelink, Richard Sylvester, Ian S. Fentiman, Jean‐Pierre Julien, Antoon Lerut, G Olthuis, J. Winter, Desmond Curran, Neil K. Aaronson and IS Fentiman and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Neurology.
In The Last Decade
F Mignolet
21 papers receiving 1.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| F Mignolet Belgium | 12 | 1.2k | 802 | 722 | 502 | 241 | 21 | 1.7k | ||
| A. J. Coldman Canada | 14 | 910 0.7× | 691 0.9× | 445 0.6× | 426 0.8× | 321 1.3× | 15 | 1.8k | ||
| Margreet H.A. Baaijens Netherlands | 17 | 869 0.7× | 749 0.9× | 605 0.8× | 378 0.8× | 527 2.2× | 22 | 2.5k | ||
| Willem J. Klokman Netherlands | 13 | 386 0.3× | 802 1.0× | 1.2k 1.7× | 252 0.5× | 802 3.3× | 14 | 2.6k | ||
| M.A. Crommelin Netherlands | 22 | 577 0.5× | 964 1.2× | 534 0.7× | 521 1.0× | 461 1.9× | 39 | 1.8k | ||
| Anthony Abner United States | 23 | 2.7k 2.2× | 1.4k 1.8× | 1.6k 2.3× | 1.1k 2.2× | 602 2.5× | 48 | 3.7k | ||
| J.A. van Dongen Netherlands | 18 | 2.0k 1.6× | 1.1k 1.4× | 1.2k 1.7× | 847 1.7× | 302 1.3× | 36 | 2.6k | ||
| Roger E. Moe United States | 23 | 1.4k 1.2× | 1.1k 1.3× | 1.0k 1.4× | 611 1.2× | 231 1.0× | 39 | 2.4k | ||
| Guy F. Robbins United States | 25 | 1.3k 1.1× | 885 1.1× | 1.0k 1.5× | 381 0.8× | 230 1.0× | 45 | 2.2k | ||
| Penny R. Anderson United States | 26 | 1.2k 0.9× | 675 0.8× | 519 0.7× | 690 1.4× | 488 2.0× | 87 | 2.4k | ||
| Carla S. Fisher United States | 24 | 769 0.6× | 740 0.9× | 350 0.5× | 792 1.6× | 209 0.9× | 99 | 1.8k |
Countries citing papers authored by F Mignolet
Since
Specialization
Citations
This map shows the geographic impact of F Mignolet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F Mignolet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F Mignolet more than expected).
Fields of papers citing papers by F Mignolet
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by F Mignolet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F Mignolet. The network helps show where F Mignolet may publish in the future.
Co-authorship network of co-authors of F Mignolet
This figure shows the co-authorship network connecting the top 25 collaborators of F Mignolet. A scholar is included among the top collaborators of F Mignolet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F Mignolet. F Mignolet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Chevalier, Marlène, et al.. (2018). In Vitro Screening of the Antibacterial and Anti- Candida Properties of Crushed Nonantimicrobial Drugs Frequently Prescribed in Nursing Homes. Research in Gerontological Nursing. 11(2). 82–90.
2.
Berthier, F., et al.. (2006). L’escarre à l’hôpital en 2003 : enquête de prévalence un jour donné. Revue d Épidémiologie et de Santé Publique. 54(6). 517–527.
3.
Julien, Jean‐Pierre, Nina Bijker, Ian S. Fentiman, et al.. (2001). Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. Cancer/Radiothérapie. 5(2). 193–194.
4.
Julien, Jean‐Pierre, Nina Bijker, Ian S. Fentiman, et al.. (2000). Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. The Lancet. 355(9203). 528–533.
5.
Tienhoven, Geertjan van, Adri C. Voogd, Johannes L. Peterse, et al.. (1999). Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). European Journal of Cancer. 35(1). 32–38.
6.
Vinholes, J., RE Coleman, Denis Lacombe, et al.. (1999). Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. British Journal of Cancer. 80(1-2). 221–228.
7.
Mauriac, L., Corinne Veyret, J. Wildiers, et al.. (1998). Combined treatment with the LHRH-agonist buserelin (LHRH-A) and tamoxifen (TAM) vs single treatment with each drug alone in premenopausal metastatic breast cancer. Final results of EORTC study 10881. Ghent University Academic Bibliography (Ghent University).
8.
Curran, Desmond, Neil K. Aaronson, G.M. Kiebert, et al.. (1998). Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: results of EORTC trial 10801. European Journal of Cancer. 34(3). 307–314.
9.
Clahsen, P C, C J van de Velde, Jean‐Pierre Julien, et al.. (1996). Improved local control and disease-free survival after perioperative chemotherapy for early-stage breast cancer. A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study.. Journal of Clinical Oncology. 14(3). 745–753.
10.
Klijn, J.G.M., C. Seynaeve, L.V.A.M. Beex, et al.. (1996). PP-8-1 Combined estroyen suppression and receptor (ER) blockade by buserelin (LHRH-A) and tamoxifen (TAM) in premenopausal metastatic breast cancer: Preliminary results of a 3-arm randomized study (EORTC 10881). European Journal of Cancer. 32. 49–49.
11.
Vinholes, J., RE Coleman, Didier Lacombe, et al.. (1996). PP-8-7 Assessment of response in bone within an EORTC randomised trial of bisphosphonate treatment (10924). European Journal of Cancer. 32. 50–50.
12.
Tomiak, Eva, M. Piccart, F Mignolet, et al.. (1996). Characterisation of complete responders to combination chemotherapy for advanced breast cancer: A retrospective EORTC breast group study. European Journal of Cancer. 32(11). 1876–1887.
13.
Clahsen, P C, C J van de Velde, Jean‐Pierre Julien, J.-L. Floiras, & F Mignolet. (1994). Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study.. Journal of Clinical Oncology. 12(6). 1266–1271.
14.
Hildebrand, Jerzy, et al.. (1994). Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. Neurology. 44(8). 1479–1479.
15.
Clahsen, P C, et al.. (1993). Perioperative adjuvant chemotherapy in early breast cancer patients, EORTC study 10854. Breast Cancer Research and Treatment. 27. 132.
16.
Clahsen, P C, et al.. (1993). Peri-operative adjuvant chemotherapy in breast cancer. The Breast. 2(3). 194–194.
17.
Paridaens, Robert, Jean-Claude Heuson, J.P. Julien, et al.. (1993). Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: a double-blind randomized study. European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group.. Journal of Clinical Oncology. 11(9). 1723–1728.
18.
Beex, L.V.A.M., et al.. (1992). Dose intensity of chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil in the elderly with advanced breast cancer. European Journal of Cancer. 28(2-3). 686–690.
19.
Ja, van Dongen, Harry Bartelink, Fentiman Is, et al.. (1992). Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial.. PubMed. 15–8.
20.
Paridaens, Robert, J Julien, Corinne Veyret, et al.. (1990). Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: Preliminary results of a double-blind randomized study of the eortic breast cancer cooperative group. The Journal of Steroid Biochemistry and Molecular Biology. 37(6). 1109–1113.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by A. J. Coldman Breakdown of academic impact, for papers by Margreet H.A. Baaijens Breakdown of academic impact, for papers by Willem J. Klokman Breakdown of academic impact, for papers by M.A. Crommelin Breakdown of academic impact, for papers by Anthony Abner Breakdown of academic impact, for papers by J.A. van Dongen Breakdown of academic impact, for papers by Roger E. Moe Breakdown of academic impact, for papers by Guy F. Robbins Breakdown of academic impact, for papers by Penny R. Anderson Breakdown of academic impact, for papers by Carla S. Fisher